Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ReNAgade Therapeutics

CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
From ReNAgade Therapeutics
Via Business Wire
ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting
From ReNAgade Therapeutics
Via Business Wire
ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
From ReNAgade Therapeutics
Via Business Wire
ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
From ReNAgade Therapeutics
Via Business Wire
ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference
From ReNAgade Therapeutics
Via Business Wire
ReNAgade Therapeutics Appoints Paul Perreault to Board of Directors
From ReNAgade Therapeutics
Via Business Wire
ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference
From ReNAgade Therapeutics
Via Business Wire
ReNAgade Therapeutics Named to the 2023 Endpoints 11
From ReNAgade Therapeutics
Via Business Wire
ReNAgade Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
From ReNAgade Therapeutics
Via Business Wire
ReNAgade Therapeutics Launches with over $300 Million in Series A Financing To Unlock the Limitless Potential of RNA Medicine
From ReNAgade Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.